Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for ...

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite control and metabolic pathways, with pharmaceutical ...

Eli LillyDemand for weight-loss drugs in India has shot up.And rivals Novo Nordisk and Eli Lilly are battling for market ...

(Reuters) -Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country.

Incidence of obesity and diabetes is rising in India, the world's most populous country, which also ranks among the worst ...

Health news highlights the booming demand for obesity drugs in India with companies like Eli Lilly and Novo Nordisk vying for ...

The demand for weight-loss medications is rapidly increasing in India, with competitors Eli Lilly and Novo Nordisk vying for ...

Eli Lilly (NYSE:LLY) drew attention on Friday after JPMorgan reiterated its bullish stance on the stock, raising its price ...

Sales of Eli Lilly’s Mounjaro double in a month; Novo Nordisk’s Wegovy enters market amid rising obesity and diabetes rates.